Expression of Her2/neu receptor in Carcinoma Gallbladder correlates significantly with advanced tumor stage

Ashai, Farzana; Ashraf, Aadil; Rashid, Arshad; Banday, Bilal Musharaf; Bhalla, Sunita; Dhawan, Shashi

doi:10.5348/ijhpd-2015-40-cr-15

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Ashai et al studied the HER2/neu expression in correlation to advanced tumour stage of gall bladder carcinoma and showed that 46% cases were score 1+, 23% were score 2+, 9% cases were 3+ and 19% cases were negative. 14 We also evaluated HER-2/neu expression in gall bladder carcinoma and found similar results. Majority of cases (48%) have score 1+, while 20% and 24% cases have score zero and 2+.…”

Section: Discussionsupporting

confidence: 55%

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

Choudhury

Deka

et al. 2021

Int J Res Med Sci

View full text Add to dashboard Cite

Background/Objective: Gall bladder carcinoma (GBC) is an aggressive malignancy with high mortality and aggressive course, with palliation as the only available option. The signs and symptoms of gall bladder arcinoma are not specific and often present late. Diagnosis is, therefore, often made at advanced stage with poorer outcomes. Identifying biomarkers and cancer specific cellular targets, that will pave the way for novel therapeutic approaches and early diagnosis for gall bladder carcinoma, is urgently needed. Proto-oncogenes (HER-2) and E-Cadherin are commonly deregulated in gallbladder cancer (GBC). This study evaluates the prognostic significance of HER-2 and E-Cadherin in GBC patients in Silchar Medical College.Our main objective was to evaluate frequency of HER-2/neu overexpression in GBC and to seek its correlation, if any with conventional clinicopathological parameters and survival.Methods: A total of 168 cases were received and evaluated for Gall Bladder cancer and control specimens were prospectively collected from 2018-2020. Immunohistochemical staining was done using monoclonal antibodies to semiquantitatively evaluate HER-2 and E-Cadherin protein expression. The criterion for HER-2 and E-Cadherin positivity was set at 10% and >5% tumor cells showing complete, membranous staining. Clinicopathological correlations were drawn with major clinical outcomes. Results: It was observed that out of 168 cases the male to female ratio is 1:5 with highest number of cases in the age group of 50-59 , i.e., 70 cases with 41.7%. The most common location in this study was fundus with 69% of cases (116 out 0f 168), most commonly presented as biliary colic with 56 number of cases. Grading was also done in 168 cases where most number of cases were moderately differentiated with 86 number of cases with a percentage of 51%. Expression of Her2Neu and E-Cadherin was evaluated where highest number of cases were seen with 1+ score in the IHC expressions of both the markers with 81 and 61 number of cases respectively. Conclusion: The increasing global incidence, late presentation leading to poor prognosis and lack of effective therapy make the management of gall bladderv carcinoma really challenging. Our study shows the abnormal expression of HER-2 and E-Cadherin expression in gall bladder carcinoma patients in Southern Assam and suggests that these two markers can be used for potential tool for early detection of gall bladder carcinoma and also can be used for targeted therapy in gall bladder carcinoma.

show abstract

Section: Discussionsupporting

confidence: 55%

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

Choudhury

Deka

et al. 2021

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…In patients with advanced breast and gastric cancer, Her-2 receptor blockers (Trastuzumab) have already been incorporated into conventional chemotherapy with good results. In gallbladder cancer, there have been reports regarding the overexpression and amplification of Her-2 (15,16,17). Scoring protocols for Her-2 expression in breast and gastric carcinomas are standardized, however, not for carcinomas arising in other body organs like the gallbladder.…”

Section: Introductionmentioning

confidence: 99%

“…Few studies have been done worldwide about overexpression of the Her-2 gene in gallbladder carcinoma (14)(15)(16)(17) but have never been performed in our country even though Pakistan has a high incidence of gallbladder cancer. This study was conducted in our population to determine the over-expression of Her-2 in gallbladder adenocarcinoma to determine the subset of patients who can get benefit from anti-Her-2 therapy.…”

Section: Introductionmentioning

confidence: 99%

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy

Zafar¹,

Afzal²,

Zafar³

et al. 2020

ACTA

View full text Add to dashboard Cite

Her-2 (ErbB-2) is an oncogene frequently overexpressed in breast and gastric adenocarcinomas, and anti-Her-2 targeted therapy can be given to such patients. Her-2 overexpression and role of anti-Her-2 targeted therapy in cases of gallbladder adenocarcinomas (GBC) are still debatable. Scoring protocols for Her-2 expression in breast and gastric carcinomas are standardized, however, not for carcinomas arising in other body organs like the gallbladder. This study is conducted to evaluate the expression of Her-2 in patients with GBC, which may benefit from targeted therapy. It is a cross-sectional study conducted on patients with GBC (n=63; 53 women and ten men). An automated immunohistochemical technique was used with an anti-ErbB2 antibody. Scoring was conducted according to the CAP (College of American Pathologists) criteria for breast cancer. Positive (3+) Her-2 staining was observed in 8/63 (12.7%). Nine cases (14.3%) showed equivocal staining (2+) pattern. All of the tumors showing Her-2 overexpression were moderately differentiated. This study indicates that a significant number of GBC cases show Her-2 overexpression. This subgroup may benefit from inhibitors of the Her-2 pathway. Standardization of scoring protocol for Her-2 expression in GBC is needed to better evaluate the predictive potential of Her-2 for the treatment of these tumors.

show abstract

Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder

Halder

Kundu

Chakraborty

et al. 2018

J Gastrointest Canc

View full text Add to dashboard Cite

Overexpression of HER2 was observed in 48% (n = 12) of adenocarcinomas, 58% (n = 7) of high-grade dysplasia, 47% (n = 8) of low-grade dysplasia, and 74% (n = 25) of intestinal metaplasia. Ki-67 index increases in a non-linear fashion as the precursor lesions progress toward malignancy. In the future, these markers might be used as a prognostic biomarker for gallbladder carcinoma and its precursor lesions and it might become a valid indication for targeted therapies for gallbladder cancer.

show abstract

Expression of Her2/neu receptor in Carcinoma Gallbladder correlates significantly with advanced tumor stage

Cited by 6 publications

References 17 publications

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy

Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder

Contact Info

Product

Resources

About